



Cite this: *Nanoscale*, 2025, **17**, 8183

A novel Janus nanomachine based on mesoporous silica nanoparticles anisotropically modified with PAMAM dendrimers for enzyme-controlled drug delivery†

Beatriz Mayol, ^a Esther García-Díez, ^a Alexander Hoppe, ^a Lucía Espejo, ^a Miranda Muñoz, ^a Marta González, ^a Anabel Villalonga, ^a Teresa Moreno, ^a Alfredo Sánchez, ^a Diana Vilela, ^a Narcisa Martínez-Quiles, ^b Paloma Martínez-Ruiz ^a and Reynaldo Villalonga ^{a*}

A masking/toposelective modification approach was employed to prepare a new organic–inorganic Janus nanomaterial by attaching ethylenediamine core polyamidoamine G-4.5 dendrimers to a defined face of mesoporous silica nanoparticles. The anisotropic colloid was then sequentially functionalized on the mesoporous face with (3-isocyanatopropyl)triethoxysilane, 1-(4-aminophenyl)-2-phenylethane-1,2-dione and β -cyclodextrin to assemble a novel H_2O_2 -sensitive gating mechanism. The Janus nanomachine was finally constructed by immobilizing glucose oxidase on the dendrimeric face. The smart nanodevice released the encapsulated payload in the presence of H_2O_2 and glucose, and was successfully evaluated for the enzyme-controlled delivery of the antitumoral drug doxorubicin into HeLa cancer cells.

Received 12th September 2024,
Accepted 23rd January 2025

DOI: 10.1039/d4nr03740e

rsc.li/nanoscale

1. Introduction

During the last decades, increased attention has been paid to designing advanced drug delivery systems aimed at improving the pharmacological, pharmacokinetics and therapeutic properties of new or conventional pharmaceutical compounds.¹ These formulated systems can improve drug stability and solubility, reduce toxicity, and enhance efficacy through on-demand time-controlled release mechanisms.²

In this context, nanomaterials engineering constitutes an emergent and interdisciplinary research area that has contributed significantly to the development of new and efficient drug release systems.^{1,3–5} In this sense, a large assortment of nanomaterials, some of them appropriately functionalized with organic ligands or active biomolecules, have been employed as building elements to construct advanced nanocarriers able to release drugs at specific sites, times and/or under demand in response to specific chemical or physical stimuli.

Mesoporous silica nanoparticles (MSNs) are inorganic nanomaterials largely employed to develop new and sophisticated drug delivery systems due to their exceptional properties, such as low toxicity, high biocompatibility and load capacity, and tunability of pore size and shape through standardized synthetic protocols.⁶ MSNs can be also easily functionalized on their outer pore surface *via* silane coupling reagents, providing the nanomaterial with tailored functionalities. In particular, mechanization of MSNs with stimuli-responsive gate-like ensembles allows on-demand delivery of the encapsulated payload with precise temporal control.^{7,8}

With the aim to design more sophisticated MSN-based smart nanocarriers for drug delivery, we previously introduced two new concepts: (i) the preparation of Janus colloids with metal nanoparticles (Au, Pt, Ir, *etc.*) and MSNs as opposite faces and their use as anisotropic “hardware” for the sequential and site-selective assembly of the encapsulation, control and release mechanisms, and (ii) the employment of enzymes as sensing and control units in the resulting device.^{9,10} Such approaches allowed easy and controlled preparation of highly selective nanomachines for smart delivery by using different metal nanoparticles, enzymes and enzyme combinations.^{11–13}

Taking into account the large variety of redox enzymes producing H_2O_2 after catalytic transformation of their substrates,¹⁴ the construction of enzyme-powered mesoporous nanomachines mechanized with H_2O_2 -sensitive gate-like ensembles stimulated our interest. However, mesoporous

^a*Nanosensors and Nanomachines Group, Faculty of Chemistry, Complutense University of Madrid, 28040 Madrid, Spain. E-mail: rvillalonga@quim.ucm.es*

^b*Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, 28040 Madrid, Spain*

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4nr03740e>



Janus nanoparticles bearing catalytically active metal nanoparticles cannot be employed to construct such nanocarriers due to the fast decomposition of H_2O_2 on such metallic surfaces.¹⁵ This limitation can be overcome by preparing new mesoporous Janus colloids provided with organic nanoparticles as opposite faces. In this sense, dendrimers constitute a good choice due to the unique properties of these synthetic and hyperbranched “soft” nanomaterials, such as nanometric size, structural uniformity with globular or ellipsoidal shape, monodispersity and high permeability of their internal cavities.^{16,17} In addition, several dendrimers are synthesized with high densities of functional groups at their surface, allowing their use as supports for the multipoint covalent immobilization of enzymes and other biomolecules.

In this paper, we describe the preparation of novel Janus nanoparticles with ethylenediamine core polyamidoamine G-4.5 dendrimers (PAMAM) and MSN opposite faces. These colloids were mechanized on the mesoporous face with a novel H_2O_2 -sensitive gate-like ensemble based on 1-(4-aminophenyl)-2-phenylethane-1,2-dione moieties supramolecularly capped with β -cyclodextrin. The anisotropic nanomaterial was also functionalized with glucose oxidase (GOx, EC 1.1.3.4) covalently immobilized on the dendritic face to act as a signaling redox enzyme. During the last years, GOx has attracted increasing interest in the biomedical field due to its inherent biocompatibility, non-toxicity, and unique catalysis against β -D-glucose.^{18,19} As a proof-of-concept, this engineered nanomachine with enzymatic control was evaluated as a smart nanocarrier for the on-command and autonomous release of tris(2,2'-bipyridyl)dichlororuthenium(II) ($\text{Ru}(\text{bipy})_3\text{Cl}_2$) and doxorubicin (Doxo) as model payloads.

2. Experimental

2.1. Materials

Ethylenediamine core polyamidoamine G-4.5 dendrimer was acquired from Dendritic Nanotechnologies Inc. (USA). Glucose oxidase from *A. niger*, (3-aminopropyl)triethoxysilane (APTES), tetraethoxysilane (TEOS), cetyltrimethylammonium bromide (CTAB), (3-isocyanatopropyl)triethoxysilane (ICPTES), *N*-hydroxysuccinimide (NHS), tris(2,2'-bipyridyl)dichlororuthenium(II) hexahydrate, β -cyclodextrin (β CD), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) and PBS were purchased from Sigma-Aldrich (USA). Iscove's modified Dulbecco's medium (IMDM), fetal bovine serum (FBS), WGA (wheat germ agglutinin) conjugated to Alexa Flour-488 and Hoechst 333442 were purchased from Thermo Fisher. Doxorubicin (Doxo) was acquired from Sequoia Research Products Ltd (USA). Solvents were provided by Scharlau (Spain). All other reagents were of analytical grade.

2.2. General techniques

Spectrophotometric analyses were performed with an Ultrospec™ 8000 Dual Beam UV/VIS spectrophotometer (Biochrom, UK). ^1H NMR and ^{13}C NMR measurements were

performed with Bruker DPX 300 MHz equipment (USA). FT-IR spectra were measured on a PerkinElmer Spectrum 400 Series spectrometer (PerkinElmer, USA). Transmission electron microscopy (TEM) was performed with a JEOL JEM-2100 microscope (JEOL Ltd, Japan). Powder X-ray diffraction (XRD) was performed with an X'Pert MRD diffractometer (PANalytical B.V., The Netherlands). Nitrogen adsorption/desorption isotherms and pore size distributions were determined with an ASAP 2020 Physisorption Analyzer (Micromeritics, USA). Thermal analysis was performed with TA Instruments SDT-Q600 apparatus (USA).

2.3. Synthesis of 1-(4-aminophenyl)-2-phenylethane-1,2-dione (APPD)²⁰

Acetophenone (484 mg, 4.0 mmol), $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (683 mg, 4 mmol) and I_2 (303 mg, 1.2 mmol) were dissolved in 20 mL of anhydrous DMSO under an Ar atmosphere. The reaction mixture was stirred at 100 °C until complete reaction of acetophenone, as determined by TLC. The mixture was then cooled to room temperature, and 448 mg (4.8 mmol) of aniline was added. The temperature was adjusted to 100 °C and the mixture was stirred for 12 h under an Ar atmosphere. After cooling to room temperature, 30 mL of water was added, and the synthesized compound was extracted with EtOAc (3 × 20 mL). The combined EtOAc extracts were dried with Na_2SO_4 and the solvent eliminated using a rotovap. The crude product was then purified by chromatography under isocratic conditions on a silica column using *n*-hexane : EtOAc (5 : 1) as eluent. Yield: 60% (553 mg, bright yellow powder). ^1H NMR (300 MHz, CDCl_3) δ /ppm: 7.89 (d, J = 7.00 Hz, 2 H), 7.71 (d, J = 8.69 Hz, 2 H), 7.55 (d, J = 7.36 Hz, 1 H), 7.41 (t, J = 8.20 Hz, 2 H), 6.56 (d, J = 8.77 Hz, 2 H). ^{13}C NMR (75 MHz, CDCl_3) δ /ppm: 195.5, 192.7, 152.9, 134.5, 133.5, 132.7, 129.9, 128.9, 123.2, 114.0. FT-IR: 3505 cm^{-1} , 3376 cm^{-1} , 2918 cm^{-1} , 1630 cm^{-1} , 1578 cm^{-1} . MP: 128–129 °C.

2.4. Preparation of Janus nanoparticles (N_1)

MSNs (N_0) were first prepared by dissolving 1.0 g of CTAB in 0.48 L of water and further adding 3.5 mL of 2.0 mol L^{-1} NaOH solution. The mixture was heated to 80 °C and 5.0 mL of TEOS was added dropwise under vigorous magnetic stirring and constant temperature. The mixture was stirred for 2 h under the same conditions and, after cooling, the resulting white solid was filtered, exhaustively washed with water and methanol, and dried at 60 °C. The solid was finally calcined at 550 °C for 5 h.

To prepare the PAMAM-MSN Janus nanoparticles, 200 mg of solid N_0 was dispersed in 10 mL of 1.0 μM CTAB in 6.7% EtOH aqueous solution. The mixture was heated to 75 °C and 1.0 g of paraffin wax was then added. After melting the paraffin wax, the mixture was stirred at 25 000 rpm for 10 min and at 75 °C by using an Ultra Turrax T-10 homogenizer (IKA, Germany). The resulting emulsion was then magnetically stirred at 4000 rpm for 1 h at 75 °C, further cooled to room temperature, and mixed with 10 mL of MeOH. The unmasked faces of the MSNs were then provided with primary amino



groups by adding 200 μ L of APTES, and stirring the mixture for 3 h at room temperature. The mixture was further filtered, and the resulting solid was exhaustively washed with MeOH and then dispersed in 25 mL of methanol.

In parallel, 10 μ L of PAMAM was first dissolved in 4.81 mL of 0.1 mol L^{-1} sodium phosphate buffer, pH 6.0, and then 100 μ L of 0.2 μ g mL^{-1} EDAC and 80 μ L of 0.2 μ g mL^{-1} NHS were added. The mixture was stirred at 4 °C for 1 h, then diluted up to 120 mL with 0.1 mol L^{-1} sodium phosphate buffer, pH 7.5, and mixed with the methanolic dispersion of paraffin-masked amino-activated MSNs. The mixture was stirred at room temperature for 18 h, and further centrifuged. The resulting solid was sequentially washed with MeOH, mixtures of MeOH:CHCl₃ 2:1, 1:1 and 1:2, and finally with CHCl₃ until total elimination of the paraffin wax. The PAMAM-MSN Janus nanoparticles (N₁) were kept in a desiccator until use.

2.5. Preparation of gated and Ru(bipy)₃Cl₂-loaded Janus nanoparticles (N₂)

A dispersion of 50 mg of solid N₁ in 3.0 mL of anhydrous toluene was mixed with 50 μ L of ICPTES and stirred at room temperature for 18 h. The mixture was centrifuged, and the solid was 3-times washed with toluene and further redispersed in 1.0 mL of the same solvent. The synthesized APPD (45 mg) was dissolved in 2.0 mL of toluene, and mixed with the nanoparticle suspension. The mixture was stirred at room temperature for 18 h, centrifuged and the solid was 3-times washed with toluene. The 1-(4-aminophenyl)-2-phenylethane-1,2-dione-branched MSNs were dried at 60 °C for 12 h, and kept in a desiccator until use.

To prepare the dye-loaded nanoparticles, the MSNs previously modified were dispersed in 3.0 mL of 0.1 mol L^{-1} sodium phosphate buffer, pH 7.5, containing 25 mg of Ru(bipy)₃Cl₂. The mixture was stirred overnight at room temperature, and then 60 mg of β CD was added. The mixture was kept under continuous stirring for 18 h at room temperature, then centrifuged and the resulting solid N₂ was exhaustively washed with the same phosphate buffer, dried at 60 °C, and kept in a desiccator until use.

2.6. Preparation of the dye-loaded enzyme-controlled nanomachine (N₃)

The nanomachine N₃ was prepared by dispersing 10 mg of N₂ nanoparticles in 1.0 mL of cold 0.1 mol L^{-1} sodium phosphate buffer, pH 6.0, containing 5 mg of EDAC and 5 mg of NHS. The mixture was stirred for 30 min at 4 °C, centrifuged and 3-times washed with cold 0.1 mol L^{-1} sodium phosphate buffer, pH 7.5, and finally redispersed in 1.0 mL of the same cold buffer. Glucose oxidase (1.2 mg) was added, and the mixture was stirred overnight at 4 °C. The solid was purified by centrifugation, 3-times washed and redispersed in 1.0 mL of the same cold buffer. The dispersion of the nanomachine N₃ was stored in a refrigerator until use.

2.7. Preparation of the drug-loaded enzyme-controlled nanomachine (N₄)

The Doxo-loaded nanomachine was prepared as previously described in Sections 2.5 and 2.6, but by dispersing 10 mg of solid N₂ in 4 mL of 1.88 mg mL^{-1} Doxo solution in 0.1 M sodium phosphate buffer, pH 7.5, instead of using the model dye. The dispersion of the resulting nanomachine N₄, at 10 mg mL^{-1} final concentration in 0.1 mol L^{-1} sodium phosphate buffer, pH 7.5, was kept in a refrigerator until use. Similar nanomachines without the Doxo payload (N_{4A}) and without Doxo and GOx (N_{4B}) were also prepared as controls for cell viability assays.

2.8. Release assays

Solid N₃ was dispersed in 100 mmol L^{-1} sodium phosphate buffer, pH 7.5, at 3.0 mg mL^{-1} final concentration. For release assays, samples of 2.5 mL were employed in each batch experiment. Glucose at 0.05–0.1 mol L^{-1} or H₂O₂ at 0.1–1.0 mol L^{-1} final concentration was added under continuous stirring to trigger the gate-opening mechanism, and the released dye was monitored spectrophotometrically at 454 nm in time intervals after centrifugation. In parallel, control experiments were performed by using N₃ dispersions without addition of glucose.

2.9. Cell culture

HeLa human cervix adenocarcinoma cells (ATCC) were grown in Iscove's modified Dulbecco's medium (IMDM) (25 mM D-glucose) supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin 100 U mL^{-1} and streptomycin 100 μ g mL^{-1} , Invitrogen, Fisher Scientific). The cells were cultured at 37 °C in a humidified 5% CO₂ atmosphere and subcultured twice a week by trypsinization.

2.10. MTT cell viability assay

Cell viability was determined using the standard tetrazolium salt MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay.²¹ 10 000 HeLa cells were seeded per well in a 96-well plate in a volume of 160 μ L of medium.

The following day, the cells were incubated at 4 °C for 15 min to synchronize them for the endocytosis. Then, the medium was removed and the nanoparticles N₄ (100 μ g mL^{-1}) were added in D-PBS (Dulbecco's phosphate solution with calcium and magnesium) during a 30 min incubation. Control wells without nanoparticles contained D-PBS. After the cells were washed twice with D-PBS, different media containing 5% FBS and antibiotics (penicillin 100 U mL^{-1} and streptomycin 100 μ g mL^{-1}) were added: DMEM with 0, 25, 50, and 100 mM glucose and incubated during 24 h.

The next day, 20 μ L of MTT (5 mg mL^{-1} in PBS) was added to the cells and incubated for 3 hours at 37 °C. Then, the medium was replaced with 150 μ L of DMSO and incubated for 1 hour. Finally, the absorbance was measured at 490 nm using a Biotek ELX800 absorbance microplate reader.



2.11. Confocal microscopy

Internalization and cargo delivery studies using N_4 were performed on HeLa cells. For this purpose, 60 000 HeLa cells were seeded in 24-well plates, with each well covered by a 12 mm diameter glass coverslip, and placed in a CO_2 cell incubator at 37 °C and allowed to attach for 24 h. Next, we proceeded as above for 0, 25, and 100 mM glucose-supplemented DMEM.

After 4, 6, and 24 hours of incubation, the cells were fixed with 10% formalin solution (Sigma) in PBS at room temperature and permeabilized with 0.1% Triton X-100 for 5 min. After 3 washes with PBS, cells were blocked with 2% BSA in PBS for 10 min. Then the cells were stained with 2 μ g mL^{-1} WGA (wheat germ agglutinin) conjugated to Alexa Flour-488 for 10 min and secondly with 1 μ g mL^{-1} Hoechst 33342 for 5 min. Both incubation periods were protected from light and immediately followed by 3 washes with PBS.

The coverslips were mounted on microscope slides and examined under an Olympus Fluoview-1200 confocal laser scanning microscope (Olympus Life Science, UCM microscope facility), using a 60 \times oil immersion objective. Images at a resolution of 2048 \times 2048 pixels were processed with Fiji Image J software (<https://imagej.net/software/fiji/>).

2.12. Fluorescence microscopy

Cell morphology and internalization of nanoparticles were observed with a Zeiss Axio Imager A1 fluorescence microscope coupled to a Zeiss AxioCam 202 mono-camera while using ZEN 3.6 Blue Edition software. For this purpose, 40 000 cells per well were seeded onto 12-well plates, treated with N_4 and glucose and further stained as previously described.

3. Results and discussion

The novel organic–inorganic PAMAM–MSN Janus nanoparticles were prepared according to the experimental protocol represented in Scheme 1. To assemble the anisotropic nanomaterial, a mask-protecting assisted site-selective modification approach was employed by partially confining the N_0 mesoporous nanoparticles at the interface of a Pickering emulsion, using paraffin wax as oil phase.⁹ The exposed nanoparticle surface was then enriched with reactive primary amino groups

by modification with APTES, allowing further attachment of carboxylic acid-terminated PAMAM G-4.5 molecules through a carbodiimide-mediated reaction.

To characterize the resulting Janus nanoparticles, which was obtained in 43% yield, TEM analysis was performed and representative images are shown in Fig. 1. The anisotropic colloid N_1 showed a similar quasi-spherical morphology to that of the initial mesoporous silica nanoparticles N_0 , with an average particle diameter of 102 ± 7 nm and an MCM-41 type channel-like mesoporous structure. To further visualize the attached PAMAM dendron molecules, the nanomaterial was previously stained with aqueous sodium phosphotungstate.²² No significant staining was observed for N_0 , but TEM images of N_1 confirmed the anisotropic morphology of the modified nanoparticles, showing stained regions corresponding to the dendritic moieties covalently attached to the mesoporous nanomaterial.





Fig. 1 Representative TEM images of solids N_0 (A) and N_1 (B) before (1) and after staining with sodium phosphotungstate (2) or covalent attachment of Au nanoparticles (3).



Scheme 1 Preparation of PAMAM–MSN Janus nanoparticles N_1 from mesoporous silica nanoparticles N_0 .



To reinforce our hypothesis on the toposelective attachment of PAMAM molecules on a preferential face of N_0 , the carboxylic acid residues at the surface of the dendrimer in the N_1 Janus colloids were modified with cystamine, and Au nanoparticles were further attached as nanosized markers. For comparison, a similar protocol was followed with raw N_0 nanoparticles. TEM images revealed that Au nanoparticles were not attached to N_0 , but metal colloids were clearly associated with a preferential face of the PAMAM-MSN Janus nanoparticles. An additional experiment was also performed to demonstrate the attachment of PAMAM moieties to mesoporous silica nanoparticles in the anisotropic colloid by the covalent immobilization of the enzyme horseradish peroxidase on the carboxylic acid-enriched dendrimer surface. A colorimetric enzymatic assay revealed that only 30 mU of peroxidase per milligram of nanoparticles was immobilized on raw N_0 , probably associated with the non-covalent adsorption of the enzyme on the highly porous nanomaterial surface. In contrast, the enzymatic activity immobilized on the Janus nanomaterials reached 400 mU mg⁻¹, due to the presence of the PAMAM molecules acting as excellent supports for the multipoint attachment of the catalytically active protein.


As is represented in Scheme 2, N_1 nanoparticles were further provided on the mesoporous face with a novel H₂O₂-sensitive ligand by sequential attachment of (3-isocyanatopropyl)triethoxysilane (ICPTES) and 1-(4-aminophenyl)-2-phenylethane-1,2-dione (APPD). Loading the pores of nanoparticles with the reporter dye and capping the dione derivative with β -cyclodextrin yielded the solid N_2 . Fig. 1S in the ESI[†] shows the FT-IR spectra of these nanomaterials. All nanoparticles reveal the characteristic peaks of mesoporous silica nanoparticles with main bands at 3430 cm⁻¹, 1090 cm⁻¹, 800 cm⁻¹ and 460 cm⁻¹ attributed to O-H, Si-OH, SiO₄ and Si-O vibrations.¹⁰⁻¹³ The spectra of N_1 and N_2 nanoparticles show broad peaks at 3430 cm⁻¹ corresponding to the stretching of the O-H and N-H groups in the dendrimer. These spectra also

show peaks at 2925 cm⁻¹ and 1550 cm⁻¹ ascribed to the stretching and bending of C-H groups, respectively, suggesting the presence of PAMAM and APTES in the nanomaterial. The last peak could also be ascribed to C=C stretching in the aromatic rings of APPD residues. Small bands at 1480–1340 cm⁻¹ spectra proved the presence of the encapsulated ruthenium complex in N_2 ,²³ while the shoulder peak at 1160 cm⁻¹ could be ascribed to the C-OH stretching in the β CD moieties.

Thermogravimetric analysis revealed that all nanoparticles experienced a primary weight loss at temperatures up to 92 °C due to the thermal-induced desorption of physically adsorbed H₂O molecules (Fig. 2S in the ESI[†]). At higher temperatures up to 1000 °C, N_0 exhibited a slight weight loss of only 3% due to the thermal decomposition of pendant hydroxyl groups on the nanoparticle surface. In contrast, N_1 showed a second transformation with a maximum rate of thermal-induced decomposition at 567 °C, which could be ascribed to the loss of pendant APTES groups and PAMAM molecules. A more complex pattern was observed for N_2 , showing three consecutive and more pronounced thermal-induced transformation processes with maximum rate of decomposition at 324 °C, 458 °C and 915 °C. These processes could be ascribed to the transformation of the organic molecules composing the gating mechanism, the silane and dendritic residues attached to the nanoparticle surface and the encapsulated ruthenium complex.

Nitrogen adsorption/desorption isotherms were measured for all nanoparticles to determine their specific surface area, pore diameter and morphology by applying the BET and BJH models. As is illustrated in Fig. 3S in the ESI[†] N_0 and N_1 showed type IV nitrogen adsorption/desorption isotherms, typical of mesoporous supports,²⁴ with BET specific surface areas of 1053 m² g⁻¹ and 482 m² g⁻¹, respectively. The large specific surface area and the absence of hysteresis loops in the corresponding isotherm suggested that all pores are highly accessible in N_0 . However, the small hysteresis loops observed at high relative pressure values in the N_1 isotherm, as well as the noticeable reduction in its specific surface area, suggested that some pores were partially blocked in this Janus material. This fact could be ascribed to the toposelective modification of the mesoporous nanoparticle with APTES and further attachment of PAMAM molecules. This hypothesis was also supported by the pore size distribution values obtained by the BJH model. As can be appreciated from Fig. 4S (ESI[†]), the average pore diameter of the mesoporous nanoparticles changed from 2.2 nm to 2.0 nm after covalent attachment of the dendritic molecules.

A completely different nitrogen adsorption/desorption behavior was observed for N_2 , showing the characteristic isotherm pattern of mesoporous materials with filled pores, with low BET specific surface area of 98 m² g⁻¹ and no appreciable porosity, suggesting all pores were filled with the reporter dye. Finally, XRD analysis for N_0 – N_2 (Fig. 5S in the ESI[†]) revealed three diffraction peaks, assigned to the (100), (110) and (200) Bragg reflections, which are consistent with the characteristic diffraction pattern of MCM-41 type mesoporous silica nano-



Scheme 2 Preparation of the enzyme-powered Janus nanomachine N_3 for controlled release. N_1 : PAMAM-MSN Janus nanoparticles; N_2 : Ru(bipy)₃Cl₂-loaded N_1 .




particles with hexagonal pore structures.²⁵ This fact was previously confirmed by TEM analysis for solids N₀ and N₁ as shown in Fig. 1.

Solid N₂ was then employed as support for the assembly of the enzyme-controlled nanomachine N₃ by covalent immobilization of glucose oxidase on the dendritic molecules. Enzymatic and protein assays revealed that 0.1 U and 0.15 µg were immobilized in each milligram of N₃, representing an immobilized specific activity of 0.7 mU mg⁻¹ enzyme. In addition, alkaline hydrolysis and spectrophotometric determination of the reporter dye revealed an amount of 3.2 mg of ruthenium complex encapsulated in each gram of N₃.

Scheme 3 presents the proposed functional mechanism for the nanomachine N₃. Upon addition of glucose as the INPUT chemical signal, the GOx-mediated catalytic transformation of

this monosaccharide yields gluconic acid and H₂O₂, and this oxidant should break the 1,2-dione linkage at the gate-like ensemble on the mesoporous face, thus releasing the reported dye as the OUTPUT signal. To demonstrate this hypothesis, the novel H₂O₂-sensitive gating mechanism in N₃ was first evaluated. Fig. 2A shows the time-course of Ru(bipy)₃Cl₂ release from N₃ in the presence and absence of H₂O₂. No significant dye release was noticed for the control experiment without the addition of the trigger. However, the concentration of dye delivered to the solution increased progressively with the time of incubation for the mixtures upon addition of H₂O₂. It was also noticed that the release was higher for higher concentrations of the trigger. These facts suggest that H₂O₂ disrupts the gating ensemble on the nanomachine pore surface, leading to on-command release of the encapsulated dye.

In a further experiment, glucose was employed as the trigger, and the results of this kinetics release assay are shown in Fig. 2B. Similarly to the previous experiment, no significant increase in the absorbance measured at 454 nm was observed for the control solution without glucose, suggesting that the nanomachine N₃ was tightly capped, and the dye was not released. However, a noticeable cargo release was achieved over time after the addition of glucose. This fact suggests that glucose is rapidly transformed by the integrated enzyme, leading to the production of H₂O₂ with consequent disruption of the 1-(4-aminophenyl)-2-phenylethane-1,2-dione based gate-like ensemble at the mesoporous face thus promoting the release of the encapsulated Ru(bipy)₃Cl₂ complex, as represented in Scheme 3. It was also demonstrated that this autonomous release was highly selective, as illustrated in Fig. 6S in the ESI.† In fact, negligible dye release from N₃ was observed after 120 min of incubation in the presence of lactose, sucrose, galactose or fructose at 100 mmol L⁻¹ final concentration.



Scheme 3 Proposed mechanism for the enzyme-powered Janus nanomachine N₃ for on-command controlled release.




Fig. 2 (A) Kinetics of dye release from the nanomachine N₃ in 100 mM sodium phosphate buffer, pH 7.5, in the absence (□) and the presence of H₂O₂ at 0.1 M (■), 0.5 M (○) and 1.0 M (●). (B) Kinetics of dye release from the nanomachine N₃ in the same buffer, in the absence (□) and the presence of glucose at 0.05 M (■), 0.1 M (○) and 0.5 M (●). Substrates were added after 1 h of incubation. 100% represents maximum dye release in each experiment.

However, maximum release capacity was exhibited for N_3 incubated with glucose under similar experimental conditions.

Once the H_2O_2 -sensitive gating mechanism and nanomachine operation were confirmed, a similar enzyme-powered smart nanocarrier N_4 was prepared but using the antitumoral drug Doxo as cargo. Nanoparticle hydrolysis and spectrophotometric determination revealed that N_4 contained 33 μ g of Doxo per milligram of nanocarrier, representing 4.4% of encapsulation efficiency. An immobilized specific activity for GOx of 0.71 $mU\ mg^{-1}$ enzyme was also confirmed.

As is reported in Fig. 3A, N_4 was absolutely capped when incubated in 100 $mmol\ L^{-1}$ sodium phosphate buffer, pH 7.5, and consequently, no Doxo release was noticed. However, a time-dependent drug release was observed upon addition of glucose at 100 $mmol\ L^{-1}$ final concentration, suggesting that this monosaccharide triggers the cargo delivery through a similar mechanism proposed for N_3 . Accordingly, N_4 was evaluated as a smart nanocarrier for Doxo delivery in *in vitro* experiments using HeLa cancer cells as the test model.

Cell viability studies were initially performed by incubating HeLa cells for 24 h with suspensions of nanoparticles at 100 $\mu\text{g mL}^{-1}$ final concentration, and viable cells were further determined by using the MTT assay.²¹ As is illustrated in Fig. 3B, viability of HeLa cells is lower in the absence of glucose because this sugar is needed as a carbon source for cell growth and maintenance. HeLa cells remain viable in the absence of the nanoparticles, but these nanomaterials seem to be toxic for the cells, causing them significant death when applied to the incubation medium. When incubated in a medium with 25 mM glucose, cell viability was not significantly affected suggesting this sugar concentration acts as nutrient for the cells and is not enough to trigger the drug

release mechanism in N_4 . However, higher glucose concentrations of 100 mM lead to significant cell death in the presence of N_4 , suggesting the nanomachine successfully releases the drug under these conditions through the enzyme-mediated mechanism previously proposed.

With the aims being to demonstrate the cell internalization of N_4 and furthermore the enzyme-mediated autonomous drug release, confocal microscopy experiments were performed. Fig. 4 shows representative confocal images of Alexa Flour-488-labeled WGA (green), Hoescht (blue), doxorubicin (red) and merged staining (green, red and blue) for untreated HeLa cells, as well as for HeLa cells first treated with N_4 and further incubated with glucose. Two incubation times (4 h and 24 h) and different glucose concentrations (0, 25 and 100 $mmol\ L^{-1}$) were employed for this experiment.

As expected, in the absence of glucose, due to the absence of the carbon source required for cellular homeostasis, the morphology of control cells without nanoparticles seem to be affected, and additionally a significant decrease in cell density was observed, which was more accentuated after 24 h. This result agrees with those previously achieved in cell viability assays. In the presence of N_4 , a noticeable red fluorescence was observed, suggesting the Doxo-loaded nanoparticles were internalized by HeLa cells. The intensity and dispersion of the Doxo fluorescence was noticeably higher, and the morphology of HeLa cells was significantly affected when glucose was added to the incubation media. Such effects increased when both longer incubation times and higher glucose concentrations were employed. These facts suggest that the internalized nanomachines were able to release the drug in the presence of the trigger according to the mechanism previously proposed, thus stimulating cell death.





Fig. 3 (A) Kinetics of Doxo release from N_4 in 100 $mmol\ L^{-1}$ sodium phosphate buffer, pH 7.5, in the absence (black) and the presence (red) of 100 $mmol\ L^{-1}$ glucose, added after 1 h of incubation (arrow) ($n = 3$). (B) Cell viability test for HeLa cells incubated for 24 h in the absence (black) or the presence of N_{4A} (grey), N_{4B} (orange) and N_4 (blue), at 100 $\mu\text{g mL}^{-1}$ final concentration, using glucose as the trigger and the MTT assay ($n = 5$).

(A) 4 hours



(B) 24 hours




Fig. 4 Representative confocal microscopy images of HeLa cells untreated and incubated with $100 \mu\text{g mL}^{-1}$ N_4 in the presence of 0 mM, 25 mM and 100 mM glucose. Images were acquired after 4 h (A) and 24 h (B) showing Alexa Flour-488-conjugated wheat germ agglutinin (WGA), doxorubicin (Doxo), Hoechst and combined (merge) staining. Scale bar: 100 μm .

To confirm this hypothesis, HeLa cells were first treated with N_4 , then incubated with glucose and finally stained as previously described. As control, cells non-treated with the nanoparticles were employed. The resulting living cells were observed by fluorescence microscopy, and representative images are shown in Fig. 7S–9S in the ESI.†

As is illustrated in Fig. 7S,† Doxo fluorescence was not observed in control experiments based on cells non-treated with nanoparticles. However, a clear red fluorescence was detected in those incubated with N_4 , demonstrating cell internalization of these nanomaterials (Fig. 8S†). In addition, the intensity of Doxo fluorescence was higher at high glucose concentrations, suggesting major release of the drug from N_4 according to the proposed mechanism.

Fig. 9S† illustrates two HeLa cells in the same preparation but with different responses toward N_4 . On the right is a cell that internalized the nanoparticles, while on the left is

another that has not internalized them. Clear red and blue fluorescence can be observed for the cell on the right, suggesting Doxo release has caused morphological changes including high membrane permeability. Accordingly, Hoechst penetrates more easily into the cells staining the nuclei. In contrast, only Alexa Flour-488-labeled WGA green staining was observed in the HeLa cell on the left. This fact suggests that N_4 was not endocytosed, and the cell membrane was also less permeable to Hoechst staining.

4. Conclusions

An original organic–inorganic Janus nanoparticle based on mesoporous silica nanoparticles toposelectively modified with PAMAM dendrimers is herein reported. These anisotropic colloids were used to assemble an autonomous nanomachine



mechanized with novel H_2O_2 -sensitive gate-like ensembles on the mesoporous face and facilitated glucose oxidase-based enzymatic control on the dendritic face. This nanodevice was able to release the encapsulated cargo when glucose was used as the trigger, and was successfully employed to deliver the anticancer drug doxorubicin into HeLa cells. We envision that the present results can open new avenues for the further development of a large variety of autonomous nanodevices controlled by H_2O_2 producing redox enzymes for the smart and on-command delivery of drugs and other compounds.

Author contributions

BM: investigation, visualization, writing – original draft. EG, AH, LE, MM, MG, AV, TM: investigation. AS, DV: supervision. NMQ, PMR: methodology and supervision. RV: conceptualization, methodology, supervision, funding acquisition, writing – original draft.

Data availability

The data supporting this article have been included as part of the ESI.†

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from the Spanish Ministry of Economy and Competitiveness (projects CTQ2017-87954-P and PID2021-125723NB-I00), Complutense University of Madrid (project PR27/21-015), and the Spanish Ministry of Science and Innovation (project CNS2022-135255) is gratefully acknowledged. E.G. and M.G. also thank the Public Employment Service (SEPE) and NextGenerationEU funds for financial support through the Investigo Program (CT19/23-INV-M-129 and CT19/23-INV-M-56).

References

- 1 X. Cai, M. Jin, L. Yao, B. He, S. Ahmed, W. Safdar, I. Ahmad, D.-B. Cheng, Z. Lei and T. Sun, *J. Mater. Chem. B*, 2023, **11**, 716–733.
- 2 H. Yan, P. Xu, H. Cong, B. Yu and Y. Shen, *Mater. Today Chem.*, 2024, **37**, 101997.
- 3 A. Jayakumar, S. Mathew, S. Radoor, J. T. Kim, J.-W. Rhim and S. Siengchin, *Mater. Today Chem.*, 2023, **30**, 101492.
- 4 B. Q. G. Le and T. L. H. Doan, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2023, **15**, e1874.
- 5 V. Jadhav, A. Roy, K. Kaur, A. K. Rai and S. Rustagi, *Nano-Struct. Nano-Objects*, 2024, **37**, 101103.
- 6 J. Gupta, M. Quadros and M. Momin, *J. Drug Delivery Sci. Technol.*, 2023, **81**, 104305.
- 7 S.-N. Zhao, R.-H. Tang, S.-J. Deng, G.-E. Chen, J. Ye and Z.-L. Xu, *J. Mater. Sci.*, 2023, **58**, 17610–17622.
- 8 B. Mayol, V. Dato, M. Rodriguez, E. Lucena, A. Villalonga, P. Díez, S. Jimenez-Falcao, F. Sancenón, A. Sánchez, D. Vilela, P. Martínez-Ruiz, R. Martínez-Máñez and R. Villalonga, *J. Mater. Chem. B*, 2022, **10**, 6983–6990.
- 9 R. Villalonga, P. Díez, A. Sánchez, E. Aznar, R. Martínez-Máñez and J. M. Pingarrón, *Chem. – Eur. J.*, 2013, **19**, 7889–7894.
- 10 B. Mayol, S. Pradana-López, A. García, C. De La Torre, P. Díez, A. Villalonga, C. Anillo, D. Vilela, A. Sánchez, P. Martínez-Ruiz, R. Martínez-Máñez and R. Villalonga, *J. Colloid Interface Sci.*, 2024, **671**, 294–302.
- 11 B. Mayol, A. Rodríguez, A. Villalonga, C. Anillo, D. Vilela, A. Sánchez, P. Martínez-Ruiz and R. Villalonga, *J. Mater. Chem. B*, 2023, **11**, 7190–7196.
- 12 S. Jimenez-Falcao, D. Torres, P. Martínez-Ruiz, D. Vilela, R. Martínez-Máñez and R. Villalonga, *Nanomaterials*, 2021, **11**, 2492.
- 13 P. Díez, A. Sánchez, M. Gamella, P. Martínez-Ruiz, E. Aznar, C. De La Torre, J. R. Murguía, R. Martínez-Máñez, R. Villalonga and J. M. Pingarrón, *J. Am. Chem. Soc.*, 2014, **136**, 9116–9123.
- 14 A. J. C. Wahart, J. Staniland, G. J. Miller and S. C. Cosgrove, *R. Soc. Open Sci.*, 2022, **9**, 211572.
- 15 K. Liu, S. He, L. Li, Y. Liu, Z. Huang, T. Liu, H. Wu, X. Jiang, K. Liu and F. Tian, *Sci. Rep.*, 2021, **11**, 9709.
- 16 A. Sánchez, A. Villalonga, G. Martínez-García, C. Parrado and R. Villalonga, *Nanomaterials*, 2019, **9**, 1745.
- 17 M. A. Mintzer and M. W. Grinstaff, *Chem. Soc. Rev.*, 2011, **40**, 173–190.
- 18 L. H. Fu, C. Qi, Y. R. Hu, J. Lin and P. Huang, *Adv. Mater.*, 2019, **31**, 1808325.
- 19 L. H. Fu, C. Qi, J. Lin and P. Huang, *Chem. Soc. Rev.*, 2018, **47**, 6454–6472.
- 20 H. Zhang, X. Ren, W. Zhao, X. Tang and G. Wang, *Adv. Synth. Catal.*, 2017, **359**, 395–401.
- 21 T. Mosmann, *J. Immunol. Methods*, 1983, **65**, 55–63.
- 22 A. Villalonga, A. Sánchez, D. Vilela, B. Mayol, P. Martínez-Ruiz and R. Villalonga, *Microchim. Acta*, 2022, **189**, 309.
- 23 K. M. Omberg, J. R. Schoonover, J. A. Treadway, R. M. Leisure, R. B. Dyer and T. J. Meyer, *J. Am. Chem. Soc.*, 1997, **119**, 7013–7018.
- 24 A. J. Di Pasqua, K. K. Sharma, Y.-L. Shi, B. B. Toms, W. Ouellette, J. C. Dabrowiak and T. Asefa, *J. Inorg. Biochem.*, 2008, **102**, 1416–1423.
- 25 S. Schacht, M. Janicke and F. Schüth, *Microporous Mesoporous Mater.*, 1998, **22**, 485–493.

